PDCD1 and neoplasm: This combination, along with low-dose cyclophosphamide and PD-1 blockade, can inhibit the immunosuppressive function of Tregs and the PD-1/L1 axis, enhancing the CD8 + T cell responses induced by tumor vaccines [127, 128].